Thalidomide-PEG2-NH2 is primarily utilized in the development of PROTACs (Proteolysis Targeting Chimeras), a cutting-edge technology in drug discovery. It serves as a key component to target specific proteins for degradation, particularly in cancer therapy. The compound’s thalidomide moiety binds to E3 ubiquitin ligase, while the PEG2 linker enhances solubility and flexibility, enabling efficient protein degradation. Its application extends to research in targeted protein degradation for diseases like multiple myeloma and other cancers, offering a novel approach to eliminating disease-causing proteins. Additionally, it is used in biochemical studies to explore protein-protein interactions and cellular pathways.